CEL-SCI Corporation reported it has filed a request for Scientific Advice regarding Multikine* (Leukocyte Interleukin, Injection) immunotherapy for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN) with the European Medicines Agency?s (EMA?s) Scientific Advice Working Group. Europe is a high priority market for CEL-SCI, as Europe has 150,000 new annual cases of head and neck cancer, more than twice the 68,000 cases diagnosed each year in the U.S.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | -0.69% | -7.69% | -47.06% |
Apr. 23 | CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors | CI |
Feb. 14 | CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.06% | 77.73M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- CVM Stock
- News CEL-SCI Corporation
- Cel-Sci Submits Scientific Advice Filing to European Medicines Agency for Multikine in the Treatment of Head & Neck Cancer